Jim Cassidy

17.7k total citations · 4 hit papers
122 papers, 11.7k citations indexed

About

Jim Cassidy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jim Cassidy has authored 122 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 28 papers in Pathology and Forensic Medicine. Recurrent topics in Jim Cassidy's work include Colorectal Cancer Treatments and Studies (69 papers), Cancer Treatment and Pharmacology (52 papers) and Gastric Cancer Management and Outcomes (21 papers). Jim Cassidy is often cited by papers focused on Colorectal Cancer Treatments and Studies (69 papers), Cancer Treatment and Pharmacology (52 papers) and Gastric Cancer Management and Outcomes (21 papers). Jim Cassidy collaborates with scholars based in United Kingdom, United States and Switzerland. Jim Cassidy's co-authors include Arié Figer, Eduardo Díaz‐Rubio, Leonard B. Saltz, Werner Scheithauer, Florin Sirzén, Stephen Clarke, Sheryl Koski, Félix Couture, Tsai‐Shen Yang and Mikhail Lichinitser and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Jim Cassidy

119 papers receiving 11.3k citations

Hit Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin a... 2000 2026 2008 2017 2000 2008 2008 2000 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
    2000 3.0k citations Aimery de Gramont, Arié Figer et al. Journal of Clinical Oncology profile →
  2. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
    2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
  3. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
    2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
  4. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
    2000 547 citations Jim Cassidy et al. Cancer Chemotherapy and Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jim Cassidy United Kingdom 42 9.4k 3.1k 2.4k 2.3k 1.5k 122 11.7k
Alberto Sobrero Italy 45 9.6k 1.0× 3.9k 1.3× 2.7k 1.1× 2.0k 0.9× 1.7k 1.1× 207 12.1k
C. Boni Italy 34 11.0k 1.2× 5.5k 1.8× 1.7k 0.7× 3.3k 1.4× 1.7k 1.1× 122 13.9k
Eduardo Díaz‐Rubio Spain 49 8.7k 0.9× 3.5k 1.1× 2.0k 0.8× 2.4k 1.0× 2.0k 1.3× 351 12.0k
Matilde Navarro Spain 27 8.2k 0.9× 2.2k 0.7× 1.6k 0.7× 2.2k 1.0× 1.6k 1.0× 75 9.9k
Jean A. Maroun Canada 35 7.4k 0.8× 2.6k 0.9× 1.4k 0.6× 2.1k 0.9× 1.4k 0.9× 136 9.6k
Michel Seymour United Kingdom 44 9.1k 1.0× 3.6k 1.2× 1.9k 0.8× 3.1k 1.3× 1.4k 0.9× 239 12.5k
H. Cortés-Funes Spain 44 6.4k 0.7× 2.6k 0.9× 1.0k 0.4× 2.1k 0.9× 1.8k 1.2× 192 9.6k
Christophe Tournigand France 42 7.0k 0.7× 3.0k 1.0× 2.0k 0.9× 2.4k 1.0× 949 0.6× 256 9.5k
Tamas Hickish United Kingdom 45 10.2k 1.1× 4.3k 1.4× 939 0.4× 3.1k 1.3× 1.6k 1.1× 145 13.5k
Paulo M. Hoff Brazil 52 9.2k 1.0× 3.3k 1.1× 2.0k 0.9× 2.9k 1.3× 2.1k 1.4× 314 12.6k

Countries citing papers authored by Jim Cassidy

Since Specialization
Citations

This map shows the geographic impact of Jim Cassidy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Cassidy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Cassidy more than expected).

Fields of papers citing papers by Jim Cassidy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Cassidy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Cassidy. The network helps show where Jim Cassidy may publish in the future.

Co-authorship network of co-authors of Jim Cassidy

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Cassidy. A scholar is included among the top collaborators of Jim Cassidy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Cassidy. Jim Cassidy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sommeijer, Dirkje W., Qian Shi, Katrin Marie Sjoquist, et al.. (2013). PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE. Asia-Pacific Journal of Clinical Oncology. 9. 76–76. 2 indexed citations
2.
Cassidy, Jim, Leonard B. Saltz, Chris Twelves, et al.. (2011). Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology. 22(12). 2604–2609. 70 indexed citations
3.
4.
Lyman, Gary H. & Jim Cassidy. (2009). Oxford American handbook of oncology. Oxford University Press eBooks. 2 indexed citations
5.
Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 26(12). 2013–2019. 2275 indexed citations breakdown →
6.
Espie, Colin A., et al.. (2008). Cognitive and attentional changes following cognitive behaviour therapy (CBT) for persistent insomnia associated with cancer: a randomized controlled trial. SLEEP. 31. 1 indexed citations
7.
Kelly, Claire & Jim Cassidy. (2007). Chemotherapy in metastatic colorectal cancer. Surgical Oncology. 16(1). 65–70. 42 indexed citations
8.
Little, Julian, Linda Sharp, L. F. Masson, et al.. (2006). Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: A case‐control study in the Grampian region of Scotland. International Journal of Cancer. 119(9). 2155–2164. 54 indexed citations
9.
Waterston, Ashita & Jim Cassidy. (2005). Adjuvant Treatment Strategies for Early Colon Cancer. Drugs. 65(14). 1935–1947. 4 indexed citations
10.
Twelves, Chris, Charles Butts, Jim Cassidy, et al.. (2005). Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. Clinical Colorectal Cancer. 5(2). 101–107. 44 indexed citations
11.
Mano, Max S., Jim Cassidy, & Peter Canney. (2004). Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treatment Reviews. 31(1). 35–48. 15 indexed citations
12.
Twelves, Chris, Charles Butts, Jim Cassidy, et al.. (2004). XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): Post-hoc analysis of a large phase II study. Journal of Clinical Oncology. 22(14_suppl). 3555–3555. 2 indexed citations
13.
Scott, Lucy, Judith Fraser, & Jim Cassidy. (2003). Emerging drugs in colorectal cancer. Expert Opinion on Emerging Drugs. 8(1). 193–202. 1 indexed citations
14.
Cassidy, Jim & Howard S. Höchster. (2003). New oxaliplatin‐based combinations in the treatment of colorectal cancer. Colorectal Disease. 5(s3). 1–9. 8 indexed citations
15.
Gramont, Aimery de, Arié Figer, Michel Seymour, et al.. (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 18(16). 2938–2947. 3040 indexed citations breakdown →
16.
Cassidy, Jim, James Paul, M Soukop, et al.. (1997). Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemotherapy and Pharmacology. 41(2). 161–166. 51 indexed citations
17.
Dirix, Luc, Jim Cassidy, Ron Epelbaum, et al.. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. European Journal of Cancer. 32(11). 2019–2022. 45 indexed citations
18.
19.
Kaye, S. B., et al.. (1994). Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?. British Journal of Cancer. 70(4). 749–752. 5 indexed citations
20.
Cassidy, Jim, Alastair D. Burt, Ross E. Petty, & Donita B. Sullivan. (1969). Selective IgA Deficiency in Connective-Tissue Diseases. New England Journal of Medicine. 280(5). 275–275. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberto Sobrero Breakdown of academic impact, for papers by C. Boni Breakdown of academic impact, for papers by Eduardo Díaz‐Rubio Breakdown of academic impact, for papers by Matilde Navarro Breakdown of academic impact, for papers by Jean A. Maroun Breakdown of academic impact, for papers by Michel Seymour Breakdown of academic impact, for papers by H. Cortés-Funes Breakdown of academic impact, for papers by Christophe Tournigand Breakdown of academic impact, for papers by Tamas Hickish Breakdown of academic impact, for papers by Paulo M. Hoff
Rankless by CCL
2026